New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

Detalhes bibliográficos
Main Authors:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
Formato:	Journal article
Idioma:	English
Publicado em:	2005

Registos relacionados

Towards new TB vaccines
Por: Brazier, B, et al.
Publicado em: (2020)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
Por: Kalipso Chalkidou, et al.
Publicado em: (2020-04-01)

TB vaccines in clinical development
Por: Ginsberg, A, et al.
Publicado em: (2016)

TB vaccines in clinical development
Por: Ginsburg, A, et al.
Publicado em: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
Por: Mcshane, H
Publicado em: (2008)

Need for more TB vaccine field sites.
Por: Mcshane, H
Publicado em: (2009)

Development of Orphan Vaccines: An Industry Perspective
Por: Jean Lang, et al.
Publicado em: (1999-12-01)

TB vaccines in clinical development
Por: Ginsberg, AM, et al.
Publicado em: (2016)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
Por: Whelan, K, et al.
Publicado em: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
Por: Minassian, A, et al.
Publicado em: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
Por: Owiafe, P, et al.
Publicado em: (2012)

Implementation status of pharmacological studies in the development of orphan drugs
Por: Saki Yokoshiki, et al.
Publicado em: (2024-01-01)

TB vaccine development: where are we and why is it so difficult?
Por: Wilkie, M, et al.
Publicado em: (2014)

Progress and challenges in TB vaccine development
Por: Voss, G, et al.
Publicado em: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
Por: Pathan, A, et al.
Publicado em: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
Por: Sipho Sibanda, et al.
Publicado em: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
Por: Pathan, A, et al.
Publicado em: (2012)

A review of clinical models for the evaluation of human TB vaccines.
Por: O'Shea, M, et al.
Publicado em: (2016)

Advances in orphan drug development: Time to change the status and stereotype
Por: Sayanta Thakur
Publicado em: (2022-01-01)

Current status and trend of clinical development of orphan drugs in China
Por: Ziling Xiang, et al.
Publicado em: (2022-07-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
Por: Ewa Stawowczyk, et al.
Publicado em: (2019-11-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Por: Morrell, L, et al.
Publicado em: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
Por: Kathryn T. Whelan, et al.
Publicado em: (2011-01-01)

Orphan drugs and rare diseases /
Por: Pryde, David C., editor, et al.
Publicado em: (2014)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
Por: Gray, A, et al.
Publicado em: (2007)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
Por: Odutola, A, et al.
Publicado em: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
Por: Odutola, A, et al.
Publicado em: (2012)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
Por: ZHANG Shan, et al.
Publicado em: (2023-04-01)

Mechanism of coordinated access to orphan drugs
Por: DeRidder R, et al.
Publicado em: (2012-11-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
Por: Eun Young Shin, et al.
Publicado em: (2024-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
Por: Liz Morrell, et al.
Publicado em: (2017-08-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Por: Kathleen L. Miller, et al.
Publicado em: (2020-09-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
Por: McShane, H, et al.
Publicado em: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
Por: McShane, H, et al.
Publicado em: (2014)

Rare diseases and orphan drugs.
Por: Aronson, J
Publicado em: (2006)

Predictors of orphan drug approval
Por: Heemstra Harald
Publicado em: (2010-10-01)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
Por: Hans-Georg Eichler, et al.
Publicado em: (2023-01-01)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
Por: Emma Rybalka, et al.
Publicado em: (2023-05-01)

Financing drug discovery for orphan diseases
Por: Gromatzky, Austin A., et al.
Publicado em: (2014)

Sea Grant seeks new drugs from the sea
Por: W Fenical
Publicado em: (1997-07-01)